Loading...
•
Dec 31, 2023
PTC Therapeutics Q4 2023 Earnings Report
PTC Therapeutics reported strong revenue performance in Q4 2023 and is well-positioned for 2024 with potential clinical and regulatory milestones.
Key Takeaways
PTC Therapeutics announced its Q4 and full-year 2023 financial results, reporting a Q4 total revenue of $307.1 million compared to $167.4 million for the same period in 2022. The company's full-year revenue reached $937.8 million, a 34% increase year-over-year. Key milestones include advancements in regulatory submissions for sepiapterin and vatiquinone, as well as updates on clinical trials for PTC518 and utreloxastat.
Total revenue for Q4 2023 was $307.1 million, compared to $167.4 million for Q4 2022.
Full year 2023 total revenue reached $937.8 million, representing a 34% year-over-year growth.
Translarna net product revenue for Q4 2023 was $75.2 million, compared to $55.8 million for Q4 2022.
Emflaza net product revenue for Q4 2023 was $67.4 million, compared to $58.1 million for Q4 2022.
Revenue by Segment
Forward Guidance
PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million. PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between $740 million and $835 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...